The earnings call reflected strong revenue and dosage growth, successful launches, and strategic positioning for future growth through regulatory and market dynamics. However, increased costs and cash flow challenges were noted, along with uncertainties in IDN fulfillment rates.

Company Guidance

During the scPharmaceuticals' Second Quarter 2025 Earnings Conference Call, key metrics and guidance were provided, indicating robust growth and strategic advancements. The company reported $16 million in net revenue for Q2 2025, marking a 99% increase compared to Q2 2024. Approximately 20,200 FUROSCIX doses were filled, representing a 117% increase over the previous year and a 45% increase from Q1 2025. The growth was largely driven by cardiology, with nephrology starting to contribute following the launch into this area in late April. The company highlighted the anticipated impact of the Medicare Part D redesign, which is expected to continue enhancing market penetration as more patients reach their out-of-pocket maximums. Additionally, scPharmaceuticals is on track to submit a supplemental new drug application (SNDA) for an auto-injector in Q3 2025, which could result in a 75% reduction in cost of goods sold (COGS) and increased penetration rates. The company ended Q2 with $40.8 million in cash, down from $75.5 million at the end of 2024, but expects cash flows to improve with increasing revenues and a recent price increase. Overall, scPharmaceuticals expressed optimism about the future growth prospects of FUROSCIX, driven by favorable market dynamics and strategic initiatives.

Significant Revenue Growth

scPharmaceuticals generated $16 million in net revenue for Q2 2025, marking a 99% increase over Q2 2024.

FUROSCIX Doses Increase

Approximately 20,200 FUROSCIX doses were filled, representing a 117% increase over Q2 2024 and a 45% increase over Q1 2025.

Nephrology Launch Success

The nephrology launch of FUROSCIX showed faster adoption rates by nephrologists compared to cardiologists, with higher doses per prescription.

IDN Business Growth

The Integrated Delivery Network (IDN) business grew by 70% quarter-over-quarter, becoming a significant part of total sales.

Positive Impact of Medicare Part D Dynamics

An increasing number of Part D patients reached their out-of-pocket maximums, positively impacting Q2 performance and expected to enhance future market penetration.

Regulatory and Strategic Advancements

The anticipated submission of the SNDA for the auto-injector and the CMS proposed ambulatory specialty model are expected to provide future growth opportunities.

scPharmaceuticals (SCPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SCPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.23 / -	-0.75	―	―	―
Aug 07, 2025	2025 (Q2)	-0.30 / -0.34	-0.44	22.73% (+0.10)	―
May 14, 2025	2025 (Q1)	-0.30 / -0.37	-0.36	-2.78% (-0.01)	―
Mar 19, 2025	2024 (Q4)	-0.38 / -0.35	-0.35	0.00% (0.00)	―
Nov 13, 2024	2024 (Q3)	-0.30 / -0.75	-0.41	-82.93% (-0.34)	―
Aug 14, 2024	2024 (Q2)	-0.42 / -0.44	-0.36	-22.22% (-0.08)	―
May 14, 2024	2024 (Q1)	-0.44 / -0.36	-0.3	-20.00% (-0.06)	―
Mar 13, 2024	2023 (Q4)	-0.42 / -0.35	-0.3	-16.67% (-0.05)	―
Nov 08, 2023	2023 (Q3)	-0.36 / -0.41	-0.37	-10.81% (-0.04)	―
Aug 10, 2023	2023 (Q2)	-0.37 / -0.36	-0.35	-2.86% (-0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SCPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$5.01	$4.63	-7.58%
May 14, 2025	$2.24	$2.88	+28.57%
Mar 19, 2025	$3.04	$3.01	-0.99%
Nov 13, 2024	$3.91	$3.36	-14.07%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.